On The Violation Of Information Disclosure Of Listed Companies In Pharmaceutical Industry

This article uses the method of case study to select the representative of Er-kang Pharmaceutical in the listed companies in the pharmaceutical industry as the research object.First,it analyzes the irregularities in the information disclosure of Er-kang Pharmaceutical,and secondly discusses the reasons for the violations from the perspective of the enterprise itself.And further analyze the economic consequences of information disclosure violations,and finally put forward suggestions to solve the information disclosure violations.This article analyzes in detail the irregularities in the information disclosure of Alcon Pharmaceuticals: First,failure to disclose illegal production in time leads to unsafe pharmaceutical production;Second,failure to fully disclose R&D information prevents investors from fully understanding the actuality of Alcon Pharmaceuticals Circumstances;Third,the revenue and profits are not disclosed,and the profits are fictitiously increased through fictitious API income and concealed related transactions.Then analyze the reasons for the information disclosure violations of Erkang Pharmaceutical: First,the defect of corporate governance structure,unreasonable shareholding structure and lack of power check and balance mechanism provide opportunities for enterprise information disclosure violations;second,disclosure of false information driven by profit and competition..Third,the internal control system is ineffective,including lack of risk assessment,poor information and communication,and internal oversight.It also discusses the consequences caused by the violation of information disclosure rules of Erkang Pharmaceutical: First,the financing cost has increased;Second,the stock price has fallen continuously;Third,the profitability has declined.Based on this,this article puts forward the following targeted suggestions: First,improve the corporate governance structure of the company,and establish a good check and balance relationship between the general meeting of shareholders,the board of directors and the board of supervisors;Second,establish a research and development information disclosure system that combines the characteristics of the pharmaceutical industryDetailed disclosure of important R&D information;Third,improve the internal control system of enterprises,implement a risk-oriented internal control system and give full play to the role of internal audit supervision to make the company's information communication more efficient.